Revance Therapeutics, Inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery.
Revance is currently pursuing clinical development for two product candidates, topical RT001 and injectable RT002, in a broad spectrum of aesthetic and therapeutic indications. RT001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form of botulinum toxin. Revance is studying topical RT001 for aesthetic indications, such as crow's feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating). RT002 is a novel, injectable formulation of botulinum toxin designed to be more targeted and longer lasting than currently available injectable botulinum toxin products. Revance is studying injectable RT002 for aesthetic indications, such as glabellar (frown) lines and therapeutic uses, such as muscle movement disorders. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform.
As a healthcare company, our first priority is to the patients, doctors, nurses, and medical practitioners who use our products. We are focused on improving patient quality of life by developing, manufacturing, and marketing innovative therapeutic and aesthetic solutions.
Search 1.5 billion
Email & Phone#
Browse to anyone's Linkedin profile, and Contactout will find that person's email
and phone number
People also viewed these companies